Luminal b breast carcinoma

From WikiMD's WELLNESSPEDIA


Breast cancer
Mammo breast cancer wArrows.jpg
Mammograms showing a normal breast (left) and a breast with cancer (right)



Specialty Oncology
Symptoms A lump in a breast, a change in breast shape, dimpling of the skin, fluid from the nipple, a newly inverted nipple, a red scaly patch of skin on the breast






Risk factors Being female, obesity, lack of exercise, alcohol, hormone replacement therapy during menopause, ionizing radiation, early age at first menstruation, having children late in life or not at all, older age, prior breast cancer, family history of breast cancer, Klinefelter syndrome
Diagnosis Tissue biopsy, Mammography



Treatment Surgery, radiation therapy, chemotherapy, hormonal therapy, targeted therapy


Prognosis Five-year survival rate ≈85% (US, UK)
Frequency 2.1 million affected as of 2018
Deaths 627,000 (2018)


A biologic subset of breast cancer defined by low to moderate expression of genes characteristic of luminal epithelial cells including estrogen receptor (ER), and high expression of GGH, LAPTMB4, and CCNE1. This subtype of breast cancer is associated with a good prognosis, although not as favorable as the luminal A subtype.

Breast cancer subtypes[edit]

There are four main female breast cancer subtypes, including the following in order of prevalence:

  • HR+/HER2- ("Luminal A")
  • HR-/HER2- ("Triple Negative")
  • HR+/HER2+ ("Luminal B")
  • HR-/HER2+ ("HER2-enriched")

Abbreviations[edit]

  • HR stands for hormone receptor.
  • HR+ means that tumor cells have receptors for the hormones estrogen or progesterone, which can promote the growth of HR+ tumors.
  • HER2 stands for human epidermal growth factor receptor 2.
  • HER2+ means that tumor cells make high levels of a protein called HER2/neu, which has been shown to be associated with certain aggressive types of breast cancer.

At a Glance[edit]

Age-Adjusted Rate of New Breast Cases per 100,000 Women, SEER 21 2013–2017
Subtype New Cases
HR+/HER2- 87.0
HR-/HER2- 13.0
HR+/HER2+ 13.3
HR-/HER2+ 5.5
Unknown 9.7
Total 128.5

When all subtypes are combined, female breast cancer is fairly common.